
    
      Objectives: To evaluate the safety of the current standard Replagal treatment regimen of 0.2
      mg/kg given intravenously every two weeks over an additional 6 months in patients who have
      completed 10 weeks of Replagal therapy in the TKT027 study.

      Study Population: Hemizygous males with Fabry disease who are 18 years of age or older who
      have completed 10 weeks of Replagal therapy in TKT027.

      Design: This is an open-label, multi-center study that will assess the safety of 0.2 mg/kg
      every two weeks of enzyme replacement therapy with Replagal.
    
  